责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 威胜控股（03393）盘初涨超5%，截至发稿，股价上涨4.38%，现报28.14港元，成交额2883.08万港元。 威胜控股发布公告，根据恒生指数有限公司于2026年2月13日公布的恒生指数系列季度检讨结果，公司 被纳入恒生综合指数成份股，2026年3月6日（星期五）收市后实施，并于2026年3月9日（星期一）起生 效。董事会认为，此次公司股份获纳入此重要指数，充份体现投资者对公司价值与成长发展潜力表现的 认可，并有助吸引更广泛的市场关注，从而拓宽公司的投资者基础及提升公司股份交易流动性。 值得一提的是，近期，威胜控股公告旗下ADO业务非全资子公司惟远能源引入战略股东博裕投资。 威胜控股（03393）盘初涨超5%，截至发稿，股价上涨4.38%，现报28.14港元，成交额2883.08万港元。 威胜控股发布公告，根据恒生指数有限公司于2026年2月13日公布的恒生指数系列季度检讨结果，公司 被纳入恒生综合指数成份股，2026年3月6日（星期五）收市后实施，并于20 ...

Core Viewpoint - 威胜控股 has been included in the Hang Seng Composite Index, effective from March 9, 2026, following the quarterly review by Hang Seng Indexes Company on February 13, 2026, which reflects investor recognition of the company's value and growth potential [1] Group 1 - The inclusion in the Hang Seng Composite Index is expected to attract broader market attention [1] - This development will help expand the company's investor base and enhance the liquidity of its shares [1]

格隆汇2月16日丨图达通(02665.HK)宣布，根据恒生指数有限公司於2026年2月13日所刊发的公告，公司 已获恒生指数有限公司选定并纳入恒生综合指数成份股，自2026年3月9日起生效。恒生综合指数是一项 全面的香港市场指标，涵盖了在香港联合交易所有限公司主板上市的公司总市值最高的95%，可以用作 指数基金、互惠基金及业绩表现的基准。 ...

2月16日，中慧生物港交所公告，公司H股已获选定并将纳入恒生综合指数成份股，自2026年3月9日起 生效。恒生综合指数作为全面的H股指标，涵盖在香港交易所主板上市的累计市值最高95%的公司，并 获指数基金、互惠基金及业绩评估系统的广泛应用。 0:00 ...

董事会认为，本公司获纳入恒生综合指数成份股，反映资本市场对本公司业务表现及增长前景的认同。 董事会相信，此次纳入将有助于扩大本公司股东基础，提升H股的交易流通性，并进一步增强本公司的 声誉及品牌知名度。 智通财经APP讯，中慧生物-B(02627)发布公告，本公司H股已获选定并将纳入恒生综合指数成份股，自 2026年3月9日起生效。恒生综合指数作为全面的H股指标，涵盖在香港交易所主板上市的累计市值最高 95%的公司，并获指数基金、互惠基金及业绩评估系统的广泛应用。 ...

董事会认为，公司获纳入恒生综合指数成份股，反映资本市场对公司业务表现及增长前景的认同。董事 会相信，此次纳入将有助于扩大公司股东基础，提升H股的交易流通性，并进一步增强公司的声誉及品 牌知名度。 格隆汇2月16日丨中慧生物-B(02627.HK)发布公告，公司H股已获选定并将纳入恒生综合指数成份股， 自2026年3月9日起生效。恒生综合指数作为全面的H股指标，涵盖在香港交易所主板上市的累计市值最 高95%的公司，并获指数基金、互惠基金及业绩评估系统的广泛应用。 ...

Core Viewpoint - Silver诺医药-B (02591) has seen its stock price increase by over 5%, marking three consecutive days of gains, currently trading at 43.42 HKD with a transaction volume of 7.6433 million HKD [1] Group 1: Stock Performance - The stock price of Silver诺医药-B has risen by 5.03% [1] - The current trading price is 43.42 HKD [1] - The transaction volume reached 764.33 million HKD [1] Group 2: Market Inclusion - Silver诺医药 has been included in the Hang Seng Composite Index as part of the quarterly review results [1] - The change will take effect on December 8, 2025 [1] Group 3: Company Overview - Silver诺医药 is focused on the field of metabolic diseases [1] - The company has multiple innovative drug development pipelines targeting diabetes, obesity, and non-alcoholic fatty liver disease [1] - All drugs are self-developed and possess global intellectual property rights, with a comprehensive global research and market layout [1]

Core Viewpoint - Silver诺医药-B (02591) has seen a stock price increase of over 5%, marking three consecutive days of gains, currently trading at 43.42 HKD with a transaction volume of 7.6433 million HKD [1] Group 1: Stock Performance - The stock price of Silver诺医药-B has risen by 5.03% [1] - The current trading price is 43.42 HKD [1] - The trading volume reached 7.6433 million HKD [1] Group 2: Index Inclusion - Silver诺医药 has been included in the Hang Seng Composite Index, with changes effective from December 8, 2025 [1] - This inclusion is part of the quarterly review results of the Hang Seng Index series [1] Group 3: Company Overview - Silver诺医药 is focused on the field of metabolic diseases [1] - The company has multiple innovative drug development pipelines targeting diabetes, obesity, and non-alcoholic fatty liver disease, all of which are self-developed [1] - The company holds global intellectual property rights and has a comprehensive global research and market layout [1]

Core Viewpoint - Silver诺医药-B (02591) has seen a significant stock price increase, with a rise of over 30% recently, and currently up 6.11% to 40.3 HKD, with a trading volume of 23.13 million HKD [1] Group 1: Stock Performance - The stock price of Silver诺医药-B increased by over 30% yesterday [1] - As of the latest update, the stock is trading at 40.3 HKD, reflecting a 6.11% increase [1] - The trading volume reached 23.13 million HKD [1] Group 2: Market Inclusion - On November 21, the results of the Hang Seng Index series quarterly review were announced, with Silver诺医药 being included in the Hang Seng Composite Index [1] - The changes from this review will take effect on December 8, 2025 [1] Group 3: Product and Research Insights - According to a report from Shanghai Securities, Silver诺医药's Supraglutide α demonstrates good safety and efficacy in lowering blood sugar and weight [1] - The company shows significant advantages in treating chronic metabolic diseases such as diabetes, obesity, and fatty liver [1] - The listing on the Hong Kong Stock Exchange is expected to facilitate the advancement of the company's research pipeline and commercialization efforts [1]

Core Viewpoint - The announcement indicates that Ying'en Bio-B will be included in the Hang Seng Composite Index starting September 8, 2025, reflecting strong recognition of the company's performance and value by the capital market [1] Group 1 - The inclusion in the Hang Seng Composite Index is expected to expand the investor base for the company [1] - The move is anticipated to increase the trading liquidity of the company's shares [1]